Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 11/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648543 | 1.00 | MCHR1 (0.37) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL22980903 | 1.00 | MCHR1 (0.37) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL29648731 | 1.00 | MCHR1 (0.37) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL22979537 | 0.95 | MCHR1 (0.39) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL22979327 | 0.95 | MCHR1 (0.39) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL29648650 | 0.95 | MCHR1 (0.39) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL29648768 | 0.95 | MCHR1 (0.39) | MCHR1ADRA2ANPY5RMKNK1MKNK2 | |
| SCHEMBL22981140 | 0.92 | MAPT (0.36) | MKNK1MKNK2MGLLADORA2AADORA1 | |
| SCHEMBL22979040 | 0.92 | MAPT (0.36) | MKNK1MKNK2MGLLADORA2AADORA1 | |
| SCHEMBL29648649 | 0.92 | MAPT (0.36) | MKNK1MKNK2MGLLADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | claimed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | claimed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | claimed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | MCHR1 185/4885ADRA2A 207/4885NPY5R 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.